Weekly Sepsis Research Analysis
This week’s sepsis literature highlights advances in mechanistic neuroimmune pathways, precision prognostics, and innovative therapeutics. A Notch2-dependent neuroimmune mechanism links vagus nerve stimulation to protection from sepsis-associated AKI and nominates testable targets. High-dimensional cellular profiling produces a cellular risk score outperforming SOFA/APACHE II for postoperative sepsis prognostication, and a stiffness‑oriented lysosomal nanodegrader shows paradigm‑shifting cytokin
Summary
This week’s sepsis literature highlights advances in mechanistic neuroimmune pathways, precision prognostics, and innovative therapeutics. A Notch2-dependent neuroimmune mechanism links vagus nerve stimulation to protection from sepsis-associated AKI and nominates testable targets. High-dimensional cellular profiling produces a cellular risk score outperforming SOFA/APACHE II for postoperative sepsis prognostication, and a stiffness‑oriented lysosomal nanodegrader shows paradigm‑shifting cytokine clearance with large survival gains in murine sepsis. Complementary work strengthens automated, host‑depleted plasma mNGS and rapid host-response assays as diagnostic enablers, while operational and stewardship studies refine lab workflows.
Selected Articles
1. Notch signaling pathway mediates anti-inflammatory effects of vagus nerve stimulation during lipopolysaccharide-induced acute kidney injury.
In LPS-induced AKI models, vagus nerve stimulation (VNS) enhances macrophage Notch2 signaling, reduces splenic inflammation and renal injury, and upregulates transferrin linked to iron homeostasis. Macrophage-specific Notch2 knockout blunted VNS benefits, supporting a causal neuroimmune mechanism that connects CAP activation to iron regulation.
Impact: Identifies a testable neuroimmune axis (Notch2-mediated CAP) linking bioelectronic stimulation to organ protection and iron homeostasis, providing mechanistic rationale for translating VNS or Notch modulation into sepsis-associated AKI therapies.
Clinical Implications: Supports development of clinical trials of vagus nerve stimulation or pharmacologic Notch modulators for sepsis-associated AKI, and suggests transferrin/iron pathways as biomarkers or co-targets for patient selection.
Key Findings
- VNS enhanced macrophage Notch2 signaling, reducing splenic inflammation and renal tissue injury in LPS-induced AKI.
- Macrophage-specific Notch2 knockout attenuated VNS benefits, and VNS upregulated transferrin, linking CAP to iron homeostasis.
2. Integrated immune and endothelial profiling predicts 90-day mortality in postoperative sepsis and septic shock.
A prospective multicentre cohort (n=219) used high-dimensional spectral flow cytometry and unsupervised analyses to identify immune and endothelial cell subsets associated with 90-day mortality. A LASSO‑Cox cellular risk score outperformed SOFA and APACHE II for 90‑day mortality prediction and was supported by validation using public single‑cell RNA datasets.
Impact: Presents a mechanistically informed cellular prognostic signature that surpasses standard clinical scores, enabling precision risk stratification in postoperative sepsis and a pathway to bedside-translatable surrogates.
Clinical Implications: Encourages prospective external validation and development of streamlined cytometry or transcriptomic surrogate panels for ICU triage—potential to inform monitoring intensity and immune/endothelial-directed interventions.
Key Findings
- Integrated immune–endothelial profiling identified cell subsets linked to 90‑day mortality in postoperative sepsis/septic shock.
- A LASSO‑Cox–derived cellular risk score outperformed SOFA and APACHE II and was corroborated with public scRNA datasets.
3. Lysosome self-sorting nanodegraders for hepatic clearance of pathogenic serum mediators.
Describes stiffness-oriented lysosome self-sorting nanodegraders (SOLIDs) that capture serum immune mediators via engineered protein corona formation and route them to hepatic lysosomes for degradation. In murine models IL-6-targeting SOLIDs reduced serum IL-6 ~70% more than antibody therapy and increased 7‑day survival from 0% to 66.7% in sepsis.
Impact: Introduces a paradigm-shifting therapeutic modality that actively degrades circulating pathogenic mediators and outperforms antibody neutralization in preclinical sepsis survival—high translational potential if safety and scalability are addressed.
Clinical Implications: If translated, SOLID‑type nanodegraders could rapidly debulk cytokines/DAMPs in hyperinflammatory sepsis phenotypes, complementing or replacing cytokine‑directed antibodies; immediate next steps are large-animal toxicology, immunogenicity, and early-phase human studies.
Key Findings
- Rigid-core SOLIDs direct captured serum mediators to hepatic lysosomes via engineered protein coronas, achieving near-quantitative lysosomal accumulation.
- IL-6-capturing SOLIDs reduced serum IL‑6 ~70% more than IL‑6 antibody therapy and improved murine sepsis 7‑day survival from 0% to 66.7%.